Translate
Travere Therapeutics, Inc.
About
Travere Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 27 2026
Travere Therapeutics to Report First Quarter 2026 Financial Results
Apr 14 2026
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
Apr 13 2026
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS
Feb 19 2026
Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Feb 12 2026
Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results